CLSD241220P5000
- 0.00
- 0.000.00%
Clearside Biomedical Newsroom
Clearside Biomedical Is Maintained at Buy by Chardan Capital
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position
Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Clearside Biomedical Analyst Ratings
Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Clearside Biomedical Is Maintained at Buy by Chardan Capital
Clearside Biomedical Price Target Maintained With a $6.00/Share by Chardan Capital
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
A Quick Look at Today's Ratings for Clearside Biomedical(CLSD.US), With a Forecast Between $5 to $6
Clearside Biomedical's CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating With a $6.00 Target
Clearside Biomedical Analyst Ratings
Buy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market Position
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Clearside Biomedical's CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating With $5 Price Target
JMP Securities Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Clearside Biomedical: A Strong Buy on Promising ODYSSEY Trial Outcomes and Market Re-Rating Potential
JonesTrading Initiates Clearside Biomedical(CLSD.US) With Buy Rating, Announces Target Price $6